BR112016000282A2 - uso de antagonista de vegf em tratamento de retinopatia da prematuridade - Google Patents
uso de antagonista de vegf em tratamento de retinopatia da prematuridadeInfo
- Publication number
- BR112016000282A2 BR112016000282A2 BR112016000282A BR112016000282A BR112016000282A2 BR 112016000282 A2 BR112016000282 A2 BR 112016000282A2 BR 112016000282 A BR112016000282 A BR 112016000282A BR 112016000282 A BR112016000282 A BR 112016000282A BR 112016000282 A2 BR112016000282 A2 BR 112016000282A2
- Authority
- BR
- Brazil
- Prior art keywords
- vegf antagonist
- prematurity
- retinopathy
- treatment
- baby
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
- A61F9/00823—Laser features or special beam parameters therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845073P | 2013-07-11 | 2013-07-11 | |
| PCT/IB2014/063003 WO2015004626A2 (en) | 2013-07-11 | 2014-07-10 | Use of a vegf antagonist in treating retinopathy of prematurity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016000282A2 true BR112016000282A2 (pt) | 2017-12-12 |
Family
ID=51211284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016000282A BR112016000282A2 (pt) | 2013-07-11 | 2014-07-10 | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
Country Status (14)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US10973867B2 (en) | 2015-12-30 | 2021-04-13 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン,エルエルシー | Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法 |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| AU2008325142A1 (en) * | 2007-11-07 | 2009-05-14 | Anthrogenesis Corporation | Use of umbilical cord blood in the treatment of premature birth complications |
| CN102215875B (zh) * | 2008-10-16 | 2014-08-06 | 凯瑟琳·科根·法瑞纳斯 | 持续药物递送系统 |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| JP2012525415A (ja) * | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| WO2013057183A1 (en) * | 2011-10-20 | 2013-04-25 | Avienne Pharmaceuticals Gmbh | Compositions for controlling vascularization in ophthalmological and dermatological diseases |
| BR112015003658B1 (pt) * | 2012-08-21 | 2022-09-27 | Opko Pharmaceuticals, Llc | Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal |
-
2014
- 2014-07-10 JP JP2016524933A patent/JP2016523956A/ja active Pending
- 2014-07-10 BR BR112016000282A patent/BR112016000282A2/pt not_active IP Right Cessation
- 2014-07-10 HK HK16109250.8A patent/HK1221231A1/zh unknown
- 2014-07-10 EP EP14741408.0A patent/EP3019527A2/en not_active Withdrawn
- 2014-07-10 CA CA2917813A patent/CA2917813A1/en not_active Abandoned
- 2014-07-10 KR KR1020167000259A patent/KR20160030504A/ko not_active Ceased
- 2014-07-10 TW TW103123847A patent/TW201536317A/zh unknown
- 2014-07-10 WO PCT/IB2014/063003 patent/WO2015004626A2/en not_active Ceased
- 2014-07-10 CN CN201480039605.XA patent/CN105377890A/zh active Pending
- 2014-07-10 US US14/903,435 patent/US20160159893A1/en not_active Abandoned
- 2014-07-10 AU AU2014288847A patent/AU2014288847A1/en not_active Abandoned
- 2014-07-10 MX MX2016000385A patent/MX2016000385A/es unknown
- 2014-07-10 RU RU2016104398A patent/RU2676303C2/ru not_active IP Right Cessation
- 2014-07-11 AR ARP140102578A patent/AR096893A1/es unknown
-
2017
- 2017-06-26 AU AU2017204326A patent/AU2017204326A1/en not_active Abandoned
-
2019
- 2019-07-16 AU AU2019206000A patent/AU2019206000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015004626A2 (en) | 2015-01-15 |
| AR096893A1 (es) | 2016-02-03 |
| CA2917813A1 (en) | 2015-01-15 |
| TW201536317A (zh) | 2015-10-01 |
| AU2019206000A1 (en) | 2019-08-01 |
| JP2016523956A (ja) | 2016-08-12 |
| WO2015004626A3 (en) | 2015-05-28 |
| KR20160030504A (ko) | 2016-03-18 |
| US20160159893A1 (en) | 2016-06-09 |
| RU2676303C2 (ru) | 2018-12-27 |
| RU2016104398A (ru) | 2017-08-16 |
| EP3019527A2 (en) | 2016-05-18 |
| MX2016000385A (es) | 2016-04-29 |
| HK1221231A1 (zh) | 2017-05-26 |
| AU2014288847A1 (en) | 2016-01-28 |
| CN105377890A (zh) | 2016-03-02 |
| AU2017204326A1 (en) | 2017-07-13 |
| RU2016104398A3 (cg-RX-API-DMAC7.html) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221231A1 (zh) | Vegf拮抗剂治疗早产儿视网膜病变的用途 | |
| BR112016000177A2 (pt) | usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta | |
| Draelos et al. | Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study | |
| PH12016500764A1 (en) | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk | |
| BR112015009579B1 (pt) | uso de glutamina, bifidobacterium breve e pelo menos um oligossacarídeo não digerível, e composição nutricional | |
| BR112014012628B8 (pt) | Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp | |
| BR112013024199A2 (pt) | métodos para melhorar a saúde óssea em bebês usando prebióticos | |
| MX2018008583A (es) | Composiciones que comprenden oligosacaridos de la leche humana para usar en infantes o niños pequeños para prevenir o tratar alergias. | |
| Pérez et al. | Reasons and subjective effects of cannabis use among people with psychotic disorders: a systematic review | |
| BR112018013833A2 (pt) | métodos de administração de hepcidina | |
| MX2016006574A (es) | Composiciones nutritivas adaptadas a la edad con un contenido de proteina variable. | |
| BR112012033064A2 (pt) | programação precoce de função cerebral através de alimentação com proteína de soja | |
| BR112016002276B8 (pt) | grupo de ancoragem para um fixador externo | |
| BR112015016465A2 (pt) | uso de glutamina ou de uma composição; método não-medicinal para melhora posterior da função cognitiva em um bebê muito prematuro nascido pequeno para a idade gestacional; e método não-medicinal para melhora posterior do q.i em um bebê muito prematuro nascido pequeno para a idade gestacional | |
| MX374376B (es) | Uso de un suero de leche dulce que contiene una fórmula infantil para promover el desarrollo neuronal posnatal del tracto gastrointestinal del infante, y el establecimiento de las funciones intestinales que lo controlan. | |
| BR112015021781A2 (pt) | alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes | |
| Meneguin et al. | Conforto de cuidadores formais e informais de pacientes em cuidados paliativos na atençãoprimária à saúde | |
| Suzuki et al. | Questionnaire survey on burden of medication assistance to caregiver | |
| Pineda et al. | The efficacy of Dunstan baby language in decreasing the parenting stress levels of housewives with 0-2 month old infants: A quasi-experimental study | |
| Social Security Administration | Revised Medical Criteria for Evaluating Respiratory System Disorders. Final rule | |
| Baldassarre et al. | Breastfeeding: Nutrition and Behavior. | |
| Bujan Rivas | Injection site reactions and alopecia: 5 case reports | |
| Kathirvel | Thrombocytopenia: case report | |
| Norman | Ibuprofen/valproic acid | |
| Ashok et al. | Alopecia following oral acyclovir for the treatment of Herpes simplex keratitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |